Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

RGNT

Regentis Biomaterials Ltd

May 29 • 04:00PM ET

1.85

-0.13 -6.57 %

Healthcare • Medical Instruments & Supplies • Israel • Nano • AMEX

May 29, 3:40 PMRegentis Biomaterials announces that its pivotal U.S. FDA trial of GelrinC for knee cartilage repair is now more than 50% enrolled as it advances commercialization plans.

Peers: BNGO LUCY NXGL RVP ZJYL FEMY GCTK CUPR HBIO MLSS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.67	Insider Own	52.02%	Shs Outstand	4.93M	Perf Week	-13.95%
Market Cap	9.58M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.48M	Perf Month	-36.86%
Enterprise Value	3.40M	PEG	-	EPS next Q	-	Inst Own	16.38%	Short Float	0.66%	Perf Quarter	-53.33%
Income	-13.67M	P/S	-	EPS this Y	97.19%	Inst Trans	-0.67%	Short Ratio	1.18	Perf Half Y	-
Sales	0.00M	P/B	2.02	EPS next Y	-	ROA	-336.99%	Short Interest	0.02M	Perf YTD	-72.55%
Book/sh	0.92	P/C	1.30	EPS next 5Y	-	ROE	-	52W High	8.35 -77.84%	Perf Year	-
Cash/sh	1.42	P/FCF	-	EPS past 3/5Y	11.45% -71.58%	ROIC	-287.69%	52W Low	1.82 1.64%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.64% 10.76%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-376.99%	Oper. Margin	-	ATR (14)	0.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.65	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	31.70	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.65	EPS Q/Q	-	SMA20	-15.32%	Beta	-	Target Price	10.00
Payout	-	Debt/Eq	0.25	Sales Q/Q	-	SMA50	-31.60%	Rel Volume	0.92	Prev Close	1.98
Employees	10	LT Debt/Eq	0.00	Earnings	-	SMA200	-57.83%	Avg Volume	14.01K	Price	1.85
IPO	Dec 04, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	12,863	Change	-6.57%

May-29-26 03:15PM	Regentis Biomaterials (RGNT) Targets Major Gap in Knee Cartilage Repair Market with Off-the-Shelf Regenerative Implant (NewMediaWire) -6.57%
May-28-26 03:30PM	Regentis Biomaterials (RGNT) Is 'One to Watch' (NewMediaWire)
May-26-26 03:40PM	Regentis Biomaterials (RGNT) and the Off-the-Shelf Opportunity in Knee Cartilage Repair (NewMediaWire)
Apr-16-26 08:30AM	Regentis Implements Strategy for Commercial Deployment of GelrinC(R) in Europe Through Collaboration with Humanitas Hospital and Leading Cartilage Repair Expert Prof. Elizaveta Kon (ACCESSWIRE)
Mar-17-26 08:30AM	Regentis Biomaterials Develops and Patents New Solvent-Free Manufacturing Process That Increases GelrinC Production Yield by 400% (ACCESSWIRE) +5.88%
04:15PM	Loading…
Feb-24-26 04:15PM	Regentis Biomaterials Reports 2025 Financial Results and Provides Business Update (ACCESSWIRE) +8.11%
01:11PM	Regentis Biomaterials (RGNT) Appoints New CFO/CBO as GelrinC Nears Commercial Launch (Insider Monkey)
Feb-19-26 08:30AM	Regentis Biomaterials Appoints Dr. Galit Reske as Chief Medical Officer: Brings Strong Track Record of Success in Cartilage Repair (ACCESSWIRE)
Feb-17-26 08:30AM	Regentis Expands its European Clinical Site Network to Support its Commercial and Clinical Programs (ACCESSWIRE) -10.47%
Feb-04-26 08:33AM	Regentis Biomaterials Appoints Ori Gon as Chief Financial Officer and Chief Business Officer as GelrinC Progresses Towards Commercial Launch in Europe and Advances in U.S. Phase III FDA Trial (ACCESSWIRE)
Jan-29-26 08:33AM	Regentis Expanding Pivotal Phase III GelrinC Clinical Site Network: Adding Several Leading Orthopedic Centers Across the U.S. (ACCESSWIRE)
Jan-20-26 08:33AM	Regentis' GelrinC Demonstrates Breakthrough in Regenerating Native-Like Cartilage Structure in Knee Repair on MRI Results Confirmed Using a Validated, Regulator-Accepted Method (ACCESSWIRE)
Jan-06-26 08:21AM	Regentis' GelrinC Establishes Long-Term Durability of Cartilage Repair Through Quantitative MOCART Evaluation (ACCESSWIRE)
Dec-18-25 08:35AM	Regentis Biomaterials Granted New U.S. Patent for its Off-the-Shelf Regenerative Cartilage Repair Product GelrinC (ACCESSWIRE)
Dec-05-25 04:10PM	Regentis Biomaterials Ltd. Announces Closing of Initial Public Offering (GlobeNewswire)
07:23PM	Loading…
Dec-03-25 07:23PM	Regentis Biomaterials Ltd. Announces Pricing of Initial Public Offering (GlobeNewswire)

Regentis Biomaterials Ltd. engages in the development of tissue repair solutions. It focuses on orthopedic treatments through its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue such as inflamed cartilage and bone tissue. The company was founded by Dror Seliktar and Tal Yehiel on September 1, 2004 and is headquartered in Or-Akiva, Israel.

CEO & Executive ChairmanDr. Ehud Geller Ph.D.

Chief Accounting OfficerMr. Arie Gordashnikov CPA

Co-Founder & Chief Scientific OfficerDr. Dror Seliktar Ph.D.

CFO & Chief Business OfficerMr. Ori Gon

Chief Medical OfficerDr. Galit Reske Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNT

Regentis Biomaterials Ltd

Upgrade your Finviz experience